CPA4 Overexpression Correlates with Poor Prognosis and Tumor Progression in Endometrial Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2025 Mar 16

PMID 40089797

Authors

Kang He

Jingying Zheng

Tingyu Zhang

Hao Lv

Kai Wang

Zeyu Wang

Longyun Wang

Shan Wu

Lijing Zhao

Affiliations

Soon will be listed here.

Abstract

Background: The rise in endometrial cancer rates globally calls for advanced diagnostic methods and new biomarkers. CPA4, known for its role in cancer development, has not yet been studied in relation to endometrial cancer, making it a promising research avenue.

Methods: We analyzed CPA4's mRNA expression using data from TCGA and GEO databases and validated these findings with 116 clinical samples through immunohistochemical analysis. The Ishikawa and Hec-1-A cell lines were used to examine CPA4's functionality. In addition, we conducted correlation analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and survival analysis to understand CPA4's role in endometrial cancer prognosis. A nomogram model was developed for clinical prognostic predictions.

Results: CPA4 is significantly overexpressed in endometrial cancer, correlating with tumor progression and poor prognosis. Overexpression is linked to crucial functions, such as mitosis and cell cycle. Reducing CPA4 in cell lines inhibited tumor growth and spread. Kaplan-Meier plots and Cox regression analysis confirmed CPA4's significance in prognosis, with our predictive model showing high accuracy.

Conclusions: CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, presenting a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.

References

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I . Endometrial cancer. Lancet. 2005; 366(9484):491-505. DOI: 10.1016/S0140-6736(05)67063-8. View

Crosbie E, Kitson S, McAlpine J, Mukhopadhyay A, Powell M, Singh N . Endometrial cancer. Lancet. 2022; 399(10333):1412-1428. DOI: 10.1016/S0140-6736(22)00323-3. View

Neri M, Peiretti M, Melis G, Piras B, Vallerino V, Paoletti A . Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019; 20(16):2019-2032. DOI: 10.1080/14656566.2019.1654996. View

Vergote I, Amant F, Timmerman D . Should we screen for endometrial cancer?. Lancet Oncol. 2010; 12(1):4-5. DOI: 10.1016/S1470-2045(10)70280-1. View

He K, Li J, Huang X, Zhao W, Wang K, Wang T . KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma. Front Oncol. 2023; 13:1090779. PMC: 9913269. DOI: 10.3389/fonc.2023.1090779. View

Tanco S, Zhang X, Morano C, Aviles F, Lorenzo J, Fricker L . Characterization of the substrate specificity of human carboxypeptidase A4 and implications for a role in extracellular peptide processing. J Biol Chem. 2010; 285(24):18385-96. PMC: 2881764. DOI: 10.1074/jbc.M109.060350. View

Kayashima T, Yamasaki K, Yamada T, Sakai H, Miwa N, Ohta T . The novel imprinted carboxypeptidase A4 gene ( CPA4) in the 7q32 imprinting domain. Hum Genet. 2003; 112(3):220-6. DOI: 10.1007/s00439-002-0891-3. View

Pan H, Pan J, Ji L, Song S, Lv H, Yang Z . Carboxypeptidase A4 promotes cell growth via activating STAT3 and ERK signaling pathways and predicts a poor prognosis in colorectal cancer. Int J Biol Macromol. 2019; 138:125-134. DOI: 10.1016/j.ijbiomac.2019.07.028. View

Shao Q, Zhang Z, Cao R, Zang H, Pei W, Sun T . CPA4 Promotes EMT in Pancreatic Cancer via Stimulating PI3K-AKT-mTOR Signaling. Onco Targets Ther. 2020; 13:8567-8580. PMC: 7457871. DOI: 10.2147/OTT.S257057. View

10.

Sun L, Burnett J, Guo C, Xie Y, Pan J, Yang Z . CPA4 is a promising diagnostic serum biomarker for pancreatic cancer. Am J Cancer Res. 2016; 6(1):91-6. PMC: 4759400. View

11.

Sun L, Guo C, Yuan H, Burnett J, Pan J, Yang Z . Overexpression of carboxypeptidase A4 (CPA4) is associated with poor prognosis in patients with gastric cancer. Am J Transl Res. 2016; 8(11):5071-5075. PMC: 5126350. View

12.

Zhang H, Hao C, Wang H, Shang H, Li Z . Carboxypeptidase A4 promotes proliferation and stem cell characteristics of hepatocellular carcinoma. Int J Exp Pathol. 2019; 100(2):133-138. PMC: 6540673. DOI: 10.1111/iep.12315. View

13.

Sun L, Guo C, Burnett J, Yang Z, Ran Y, Sun D . Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma. Oncotarget. 2016; 7(48):78688-78697. PMC: 5346670. DOI: 10.18632/oncotarget.12798. View

14.

Sun L, Wang Y, Yuan H, Burnett J, Pan J, Yang Z . CPA4 is a Novel Diagnostic and Prognostic Marker for Human Non-Small-Cell Lung Cancer. J Cancer. 2016; 7(10):1197-204. PMC: 4934027. DOI: 10.7150/jca.15209. View

15.

Wei C, Zhou Y, Xiong Q, Xiong M, Hou Y, Yang X . Comprehensive Analysis of CPA4 as a Poor Prognostic Biomarker Correlated with Immune Cells Infiltration in Bladder Cancer. Biology (Basel). 2021; 10(11). PMC: 8615209. DOI: 10.3390/biology10111143. View

16.

Bademler S, Ucuncu M, Tilgen Vatansever C, Serilmez M, Ertin H, Karanlik H . Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer. Biomolecules. 2019; 9(3). PMC: 6468575. DOI: 10.3390/biom9030103. View

17.

Li F, Lin Y, Sarna S, Shi X . Cellular mechanism of mechanotranscription in colonic smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2012; 303(5):G646-56. PMC: 3468553. DOI: 10.1152/ajpgi.00440.2011. View

18.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

19.

He K, Wang T, Huang X, Yang Z, Wang Z, Zhang S . PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma. J Cell Mol Med. 2023; 27(6):846-863. PMC: 10002989. DOI: 10.1111/jcmm.17697. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View